AYTU Annual Total Liabilities
$90.38 M
-$6.73 M-6.93%
30 June 2024
Summary:
As of January 23, 2025, AYTU annual total liabilities is $90.38 million, with the most recent change of -$6.73 million (-6.93%) on June 30, 2024. During the last 3 years, it has fallen by -$37.72 million (-29.45%). AYTU annual total liabilities is now -29.45% below its all-time high of $128.10 million, reached on June 30, 2021.AYTU Total Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
AYTU Quarterly Total Liabilities
$86.00 M
-$4.37 M-4.84%
30 September 2024
Summary:
As of January 23, 2025, AYTU quarterly total liabilities is $86.00 million, with the most recent change of -$4.37 million (-4.84%) on September 30, 2024. Over the past year, it has dropped by -$14.72 million (-14.61%). AYTU quarterly total liabilities is now -33.02% below its all-time high of $128.41 million, reached on March 31, 2021.AYTU Quarterly Total Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
AYTU Total Liabilities Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -6.9% | -14.6% |
| 3 y3 years | -29.4% | -26.0% |
| 5 y5 years | +227.1% | -33.0% |
AYTU Total Liabilities High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -29.4% | at low | -27.3% | at low |
| 5 y | 5-year | -29.4% | +227.1% | -33.0% | +71.3% |
| alltime | all time | -29.4% | >+9999.0% | -33.0% | >+9999.0% |
Aytu BioPharma Total Liabilities History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $86.00 M(-4.8%) |
| June 2024 | $90.38 M(-6.9%) | $90.38 M(-7.9%) |
| Mar 2024 | - | $98.09 M(-0.3%) |
| Dec 2023 | - | $98.40 M(-2.3%) |
| Sept 2023 | - | $100.72 M(+3.7%) |
| June 2023 | $97.11 M(+4.1%) | $97.11 M(-8.7%) |
| Mar 2023 | - | $106.30 M(+11.2%) |
| Dec 2022 | - | $95.62 M(-0.5%) |
| Sept 2022 | - | $96.09 M(+3.0%) |
| June 2022 | $93.31 M(-27.2%) | $93.31 M(-13.3%) |
| Mar 2022 | - | $107.68 M(-9.0%) |
| Dec 2021 | - | $118.29 M(+1.8%) |
| Sept 2021 | - | $116.23 M(-9.3%) |
| June 2021 | $128.10 M(+119.8%) | $128.10 M(-0.2%) |
| Mar 2021 | - | $128.41 M(+137.6%) |
| Dec 2020 | - | $54.05 M(+7.7%) |
| Sept 2020 | - | $50.21 M(-13.8%) |
| June 2020 | $58.28 M(+110.9%) | $58.28 M(-20.4%) |
| Mar 2020 | - | $73.25 M(+27.6%) |
| Dec 2019 | - | $57.39 M(+100.0%) |
| Sept 2019 | - | $28.70 M(+3.9%) |
| June 2019 | $27.63 M(+261.9%) | $27.63 M(+23.9%) |
| Mar 2019 | - | $22.30 M(-0.9%) |
| Dec 2018 | - | $22.50 M(+186.5%) |
| Sept 2018 | - | $7.85 M(+2.9%) |
| June 2018 | $7.64 M(-30.6%) | $7.64 M(-28.1%) |
| Mar 2018 | - | $10.62 M(-32.9%) |
| Dec 2017 | - | $15.83 M(+6.3%) |
| Sept 2017 | - | $14.89 M(+35.4%) |
| June 2017 | $11.00 M(-22.9%) | $11.00 M(+48.7%) |
| Mar 2017 | - | $7.40 M(-33.1%) |
| Dec 2016 | - | $11.06 M(-15.0%) |
| Sept 2016 | - | $13.01 M(-8.7%) |
| June 2016 | $14.26 M | $14.26 M(+222.6%) |
| Mar 2016 | - | $4.42 M(-51.7%) |
| Dec 2015 | - | $9.15 M(+15.1%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2015 | - | $7.95 M(+209.5%) |
| June 2015 | $2.57 M(+4986.9%) | $2.57 M(-73.4%) |
| Mar 2015 | - | $9.65 M(>+9900.0%) |
| Feb 2015 | - | $60.90 K(+10.3%) |
| Nov 2014 | - | $55.20 K(+9.3%) |
| Aug 2014 | $50.50 K(-99.2%) | $50.50 K(+2.0%) |
| June 2014 | $6.65 M(+5415.9%) | - |
| May 2014 | - | $49.50 K(-67.7%) |
| Feb 2014 | - | $153.40 K(+15.0%) |
| Nov 2013 | - | $133.40 K(+10.7%) |
| Aug 2013 | $120.50 K(+46.2%) | $120.50 K(+4.3%) |
| May 2013 | - | $115.50 K(+7.0%) |
| Feb 2013 | - | $107.90 K(+14.7%) |
| Nov 2012 | - | $94.10 K(+14.2%) |
| Aug 2012 | $82.40 K(+41.1%) | $82.40 K(+19.4%) |
| May 2012 | - | $69.00 K(+5.0%) |
| Feb 2012 | - | $65.70 K(-1.1%) |
| Nov 2011 | - | $66.40 K(+13.7%) |
| Aug 2011 | $58.40 K(-29.4%) | $58.40 K(-12.0%) |
| May 2011 | - | $66.40 K(+26.2%) |
| Feb 2011 | - | $52.60 K(-43.1%) |
| Nov 2010 | - | $92.40 K(+11.7%) |
| Aug 2010 | $82.70 K(+49.3%) | $82.70 K(-1.8%) |
| May 2010 | - | $84.20 K(+24.7%) |
| Feb 2010 | - | $67.50 K(+10.3%) |
| Nov 2009 | - | $61.20 K(+10.5%) |
| Aug 2009 | $55.40 K(+15.2%) | $55.40 K(0.0%) |
| May 2009 | - | $55.40 K(+5.5%) |
| Feb 2009 | - | $52.50 K(+4.8%) |
| Nov 2008 | - | $50.10 K(+4.2%) |
| Aug 2008 | $48.10 K(+17.6%) | $48.10 K(+8.6%) |
| May 2008 | - | $44.30 K(+10.2%) |
| Feb 2008 | - | $40.20 K(-6.7%) |
| Nov 2007 | - | $43.10 K(+5.4%) |
| Aug 2007 | $40.90 K | $40.90 K(+6.0%) |
| May 2007 | - | $38.60 K |
FAQ
- What is Aytu BioPharma annual total liabilities?
- What is the all time high annual total liabilities for Aytu BioPharma?
- What is Aytu BioPharma annual total liabilities year-on-year change?
- What is Aytu BioPharma quarterly total liabilities?
- What is the all time high quarterly total liabilities for Aytu BioPharma?
- What is Aytu BioPharma quarterly total liabilities year-on-year change?
What is Aytu BioPharma annual total liabilities?
The current annual total liabilities of AYTU is $90.38 M
What is the all time high annual total liabilities for Aytu BioPharma?
Aytu BioPharma all-time high annual total liabilities is $128.10 M
What is Aytu BioPharma annual total liabilities year-on-year change?
Over the past year, AYTU annual total liabilities has changed by -$6.73 M (-6.93%)
What is Aytu BioPharma quarterly total liabilities?
The current quarterly total liabilities of AYTU is $86.00 M
What is the all time high quarterly total liabilities for Aytu BioPharma?
Aytu BioPharma all-time high quarterly total liabilities is $128.41 M
What is Aytu BioPharma quarterly total liabilities year-on-year change?
Over the past year, AYTU quarterly total liabilities has changed by -$14.72 M (-14.61%)